Immunine

Human Coagulation Factor IX, the active ingredient in Immunine, is a coagulation factor presented as a sterile solution for intravenous use. It replaces deficient factor IX to manage hemophilia B in patients requiring clotting factor replacement.

GNH USA supplies Immunine as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Immunine is a recombinant factor IX product used in the intrinsic coagulation pathway for hemophilia B management.

Hemophilia B (Factor IX deficiency): replaces missing factor IX to correct the clotting defect. Bleeding episodes in hemophilia B: used to stop or prevent spontaneous or traumatic bleeding. Peri‑operative management in hemophilia B: provides hemostasis during surgical procedures.

Common Side Effects: - Infusion‑related reactions such as mild fever, chills, or headache. - Nausea or mild gastrointestinal discomfort. - Transient hypertension or mild blood pressure fluctuations. - Local site irritation at the infusion site. - Fatigue or mild malaise.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions. - Development of neutralizing inhibitors (antibodies) against factor IX. - Thrombotic events including deep vein thrombosis. - Severe hemolysis or renal impairment. - Life‑threatening bleeding due to inhibitor formation. - Disseminated intravascular coagulation (rare).

Immunine requires careful clinical monitoring and individualized dosing.

Dose individualization: dosing is based on patient’s factor IX activity levels and clinical need. Monitoring: regular assessment of factor IX plasma levels and bleeding signs is essential. Allergy history: evaluate for prior hypersensitivity to plasma‑derived or recombinant clotting products. Pregnancy and lactation: use only if benefits outweigh potential risks; data are limited. Inhibitor development: monitor for antibodies that may reduce efficacy. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunine may interact with other agents affecting coagulation.

Major Interactions (Avoid): - Concomitant use of pro‑coagulant agents (e.g., activated prothrombin complex concentrates) may increase thrombosis risk. - Concurrent anticoagulants (e.g., warfarin, direct oral anticoagulants) may counteract the therapeutic effect. - Use with other factor IX products may lead to additive clotting activity.

Moderate Interactions (Monitor Closely): - Live attenuated vaccines may have altered efficacy when administered concurrently. - Certain antibiotics that affect protein synthesis could impact product stability. - Immunosuppressive therapies may influence inhibitor development risk.